Skip to main content

Advertisement

SpringerLink
Log in

Role of long non-coding RNA in tumor drug resistance

  • Review
  • Published:
Tumor Biology

Abstract

Chemotherapy has been extensively used in tumor treatment, including either systemic or local treatment. Miserably, in many kinds of cancers, chemotherapy is gradually insensitive. The mechanisms of tumor drug resistance have been widely explored, yet have not been fully characterized. With several studies in the development of drug resistance, recent works have highlighted the involvement of non-coding RNAs in tumor development. A growing number of long non-coding RNAs (lncRNAs) have been identified as transcripts of larger than 200 nucleotides in length, which have low coding potential, but potentially coding small peptides with 50–70 amino acids. Despite so often being branded as transcriptional noise, it is becoming increasingly clear that a large number of lncRNAs are crucial molecular regulators of the processes of tumor involving the initiation and progression of human tumor. More recently, accumulating evidence is revealing an important role of lncRNA in tumor drug resistance and lncRNA expression profiling can be correlated with the evolution of tumor drug resistance. The long non-coding-RNA-mediated form of drug resistance brings yet another mechanism of drug resistance. So, exploiting the newly emerging knowledge of lncRNAs for the development of new therapeutic applications to overcome human tumor drug resistance will be significant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014;37(1):4–15.

    Article  CAS  PubMed  Google Scholar 

  2. Drinberg V, Bitcover R, Rajchenbach W, Peer D. Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Lett. 2014;354(2):290–8.

    Article  CAS  PubMed  Google Scholar 

  3. Geng M, Wang L, Chen X, Cao R, Li P. The association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancer. Diagn pathol. 2013;8:198.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19(R2):R152–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Guibert S, Zhao Z, Sjolinder M, Gondor A, Fernandez A, Pant V, et al. CTCF-binding sites within the H19 ICR differentially regulate local chromatin structures and cis-acting functions. Epigenetics. 2012;7(4):361–9.

    Article  CAS  PubMed  Google Scholar 

  7. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43(7):621–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Guo F, Guo L, Li Y, Zhou Q, Li Z. MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. Int J Clin Exp Pathol. 2015;8(12):15903–10.

    PubMed  PubMed Central  Google Scholar 

  9. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477(7364):295–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Messemaker TC, Frank-Bertoncelj M, Marques RB, Adriaans A, Bakker AM, Daha N, Gay S, Huizinga TW, Toes RE, Mikkers HM et al. A novel long non-coding RNA in the rheumatoid arthritis risk locus TRAF1-C5 influences C5 mRNA levels. Genes Immun. 2015.

  11. Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G, Li N, Cheng K, Wu M, Cheng S et al. ICAM-1-related non-coding RNA in cancer stem cells maintains ICAM-1 expression in hepatocellular carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015.

  12. Wang Y, Li Z, Zheng S, Zhou Y, Zhao L, Ye H, et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget. 2015;6(34):35684–98.

    PubMed  PubMed Central  Google Scholar 

  13. Sun J, Song Y, Chen X, Zhao J, Gao P, Huang X, et al. Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer. Oncol lett. 2015;10(1):115–20.

    PubMed  PubMed Central  Google Scholar 

  14. Ding J, Li D, Gong M, Wang J, Huang X, Wu T, et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. OncoTargets Ther. 2014;7:1625–30.

    Article  Google Scholar 

  15. Ip JY, Nakagawa S. Long non-coding RNAs in nuclear bodies. Develop Growth Differ. 2012;54(1):44–54.

    Article  CAS  Google Scholar 

  16. Brockdorff N. Noncoding RNA and Polycomb recruitment. RNA. 2013;19(4):429–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Beltran M, Puig I, Pena C, Garcia JM, Alvarez AB, Pena R, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008;22(6):756–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin. 2010;42(3):224–9.

    Article  CAS  PubMed  Google Scholar 

  19. Gong C. Maquat LE: lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3′ UTRs via Alu elements. Nature. 2011;470(7333):284–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Feng S, Yao J, Chen Y, Geng P, Zhang H, Ma X, et al. Expression and functional role of reprogramming-related long noncoding RNA (lincRNA-ROR) in glioma. J Mol neurosci MN. 2015;56(3):623–30.

    Article  CAS  PubMed  Google Scholar 

  21. Hu L, Wu Y, Tan D, Meng H, Wang K, Bai Y, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res CR. 2015;34:7.

    Article  PubMed  Google Scholar 

  22. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Disc. 2011;1(5):391–407.

    Article  CAS  Google Scholar 

  23. Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, et al. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 2015;360(2):119–24.

    Article  CAS  PubMed  Google Scholar 

  24. Chen F, Tian Y, Pang EJ, Wang Y, Li L. MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer. Cancer Gene Ther. 2015.

  25. Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 2015;6:e1665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer. 2014;13:171.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Chiyomaru T, Yamamura S, Fukuhara S, Yoshino H, Kinoshita T, Majid S, et al. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One. 2013;8(8):e70372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Qiu MT, Hu JW, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34(2):613–20.

    Article  CAS  Google Scholar 

  29. Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, et al. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012;41(1):276–84.

    CAS  PubMed  Google Scholar 

  30. Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA. 2007;13(6):890–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, Chen WS, Li B. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2015.

  32. Zhang J, Zhang H, Chen L, da Sun W, Mao C, Chen W, et al. Tang JH: beta-elemene reverses chemoresistance of breast cancer via regulating MDR-related microRNA expression. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2014;34(6):2027–37.

    Article  CAS  Google Scholar 

  33. Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, et al. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(11):10773–9.

    Article  CAS  Google Scholar 

  34. Ahn JH, Bahng H, Kim JG, Kim SB, Ahn SH, Chang H, et al. Retrospective analysis of the results of adjuvant chemotherapy in breast cancer patients with 10 or more positive nodes: nonrandomized comparison of adriamycin-containing regimens. Cancer Res Treat Off J Kor Cancer Assoc. 2002;34(2):84–90.

    Google Scholar 

  35. Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A, et al. A novel long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem Pharmacol. 2014;87(2):254–83.

    Article  CAS  PubMed  Google Scholar 

  36. Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, et al. Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol Carcinog. 2015;54(12):1656–67.

    Article  CAS  PubMed  Google Scholar 

  37. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2015.

  38. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652–63.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kobori O. International strategy in the struggle against gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 1998;1(1):1–2.

    Google Scholar 

  40. Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, et al. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells. Cell Death Dis. 2014;5:e1551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227–32.

    Article  CAS  PubMed  Google Scholar 

  42. Hang Q, Sun R, Jiang C, Li Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drugs. 2015;26(6):632–40.

    CAS  PubMed  Google Scholar 

  43. Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Legge F, Ferrandina G, Salutari V, Scambia G. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2005;16(4):iv95–101.

    Google Scholar 

  45. Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, et al. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma. 2015;62(3):432–8.

    Article  CAS  PubMed  Google Scholar 

  46. Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. 2015;7(1):108.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chirovsky D, Lich KH, Barritt AS. Screening for hepatocellular carcinoma in chronic liver disease. Ann Intern Med. 2015;162(3):238–9.

    Article  PubMed  Google Scholar 

  48. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–27.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007;26(33):4877–81.

    Article  CAS  PubMed  Google Scholar 

  50. Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci J Virtual Libr. 2007;12:3813–24.

    Article  CAS  Google Scholar 

  51. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun. 2012;425(2):468–72.

    Article  CAS  PubMed  Google Scholar 

  53. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014;281(7):1750–8.

    Article  CAS  PubMed  Google Scholar 

  54. Printz C. Colorectal cancer incidence increasing in young adults. Cancer. 2015;121(12):1912–3.

    Article  PubMed  Google Scholar 

  55. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.

    Article  CAS  PubMed  Google Scholar 

  56. Kye BH, Cho HM. Overview of radiation therapy for treating rectal cancer. Ann Coloproctol. 2014;30(4):165–74.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Xiong W, Jiang YX, Ai YQ, Liu S, Wu XR, Cui JG, et al. Microarray analysis of long non-coding RNA expression profile associated with 5-fluorouracil-based chemoradiation resistance in colorectal cancer cells. Asian Pac J Cancer Prev APJCP. 2015;16(8):3395–402.

    Article  PubMed  Google Scholar 

  58. Lee H, Kim C, Ku JL, Kim W, Yoon SK, Kuh HJ, et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cell. 2014;37(7):540–6.

    Article  Google Scholar 

  59. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 2013;8(5):e65309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Cheng N, Li X, Zhao C, Ren S, Chen X, Cai W, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep. 2015;33(2):833–9.

    CAS  PubMed  Google Scholar 

  61. Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, et al. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS One. 2015;10(5):e0114586.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72.

    Article  CAS  PubMed  Google Scholar 

  63. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(6):2403–13.

    CAS  Google Scholar 

  64. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 2002;62(21):6124–31.

    CAS  PubMed  Google Scholar 

  65. Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun. 2011;407(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  67. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92.

    Article  PubMed  Google Scholar 

  68. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.

    Article  PubMed  Google Scholar 

  69. Zhang CL, Zhu KP, Shen GQ, Zhu ZS. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. Tumour Biol J Int Soc Oncodev Biol Med. 2015.

  70. Zhu KP, Zhang CL, Shen GQ, Zhu ZS. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol. 2015;8(8):8754–73.

    PubMed  PubMed Central  Google Scholar 

  71. Li W, Jia M, Qin X, Hu J, Zhang X, Zhou G. Harmful effect of ERbeta on BCRP-mediated drug resistance and cell proliferation in ERalpha/PR-negative breast cancer. FEBS J. 2013;280(23):6128–40.

    Article  CAS  PubMed  Google Scholar 

  72. Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015.

  73. Gailhouste L, Ochiya T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol. 2013;28(4):437–51.

    CAS  PubMed  Google Scholar 

  74. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Li JT, Wang LF, Zhao YL, Yang T, Li W, Zhao J, et al. Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis. Breast Cancer Res BCR. 2014;16(5):454.

    Article  PubMed  Google Scholar 

  76. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32(11):2858–68.

    Article  CAS  PubMed  Google Scholar 

  77. Augoff K, McCue B, Plow EF. Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 2012;11:5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, et al. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS One. 2014;9(1):e86295.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National High Technology Research and Development Program of China (No. 2014AA020604).

Author information

Author notes

    Authors and Affiliations

    1. Graduate School, Anhui University of Traditional Chinese Medicine, HeFei, China

      Heng Deng

    2. Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu, 42 Bai Zi Ting Road, Nanjing, Jiangsu, 210000, China

      Heng Deng, Jun Zhang, Li Ding & Jin Hai Tang

    3. Surgery of Traditional Chinese Medicine Research Institute, Anhui University of Traditional Chinese Medicine, HeFei, China

      Jun Zhang

    4. The People Hospital of SuSong, SuSong, AnHui, China

      Heng Deng, JinJun Shi & ChunRong He

    5. Graduate School, Xuzhou Medical College, Xuzhou, China

      ZhengDong Guo

    6. Department of General Surgery, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, 139 Mei Shan Road, HeFei, AnHui, 230000, China

      Yong Hou

    Authors
    1. Heng Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jun Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. JinJun Shi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. ZhengDong Guo
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. ChunRong He
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Li Ding
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Jin Hai Tang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Yong Hou
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Jin Hai Tang or Yong Hou.

    Ethics declarations

    Conflicts of interest

    None.

    Additional information

    Heng Deng, Jun Zhang and JinJun Shi contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Deng, H., Zhang, J., Shi, J. et al. Role of long non-coding RNA in tumor drug resistance. Tumor Biol. 37, 11623–11631 (2016). https://doi.org/10.1007/s13277-016-5125-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-016-5125-8

    Keyword

    Search

    Navigation